In a range of critical announcements from
Alnylam Pharmaceuticals, their Q1 earnings are anticipated to decline. However, the company secured
FDA approval for AMVUTTRA (vutrisiran), an RNAi therapeutic designed to reduce cardiovascular death and hospitalizations associated with ATTR Amyloidosis with Cardiomyopathy. Notable analysts have praised Alnylam's strategic positioning and product advancements, establishing the company's strong market prospects. Promisingly, their AMVUTTRA gained
CHMP consensus and FDA approval, boosting its growth capabilities. The financial reports for Q4 2024 and 2025 revealed significant growth and progress. This is evident from their
$2.25B revenue target set for 2025 and solid growth of 33% in 2024. Another notable announcement concerns the retirement of longtime board member Dr. Phillip A. Sharp, a luminary in the industry. Alnylam has also unveiled interim phase 1 data for their new RNAi therapeutic, Nucresiran.
Alnylam Pharmaceuticals News Analytics from Mon, 24 Jun 2024 07:00:00 GMT to Sat, 26 Apr 2025 08:32:03 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -4
